Süleyman Halis, Demircan Berna, Karagöz Yalçin
Department of Pharmacology, Faculty of Medicine, Atatürk University, TR-25240, Erzurum,Turkey.
Pharmacol Rep. 2007 May-Jun;59(3):247-58.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the most commonly used drugs in inflammatory diseases, since they are effective in management of pain, fever, redness, edema arising as a consequence of inflammatory mediator release. Studies have shown that both therapeutic and side effects of NSAIDs are dependent on cyclooxygenase (COX) inhibition. COX isoforms have been named constitutive (COX-1) and inducible (COX-2). COX-1 catalyzes formation of cytoprotective prostaglandins in thrombocytes, vascular endothelium, stomach mucosa, kidneys, pancreas, Langerhans islets, seminal vesicles, and brain. Induction of COX-2 by various growth factors, proinflammatory agents, endotoxins, mitogens, and tumor agents indicates that this isoform may have a role in induction of pathological processes, such as inflammation. It is well known that therapy with COX inhibitors is associated with a number of side effects including gastrointestinal erosions, and renal and hepatic insufficiency. Such critical adverse reactions are mostly dependent on COX-1 inhibition. As a result of research focused on reduction of the adverse effects of NSAIDs, selective COX-2 inhibitors, such as celecoxib and rofecoxib have been developed. However, many data demonstrate that mechanisms of action of these drugs are multidirectional and complex. These drugs or their derivatives, which belong to the same group, have distinct pharmacological effects, side effects and potencies which implies that there may be more than two, five or even tens of COX isoforms.
非甾体抗炎药(NSAIDs)是炎症性疾病中最常用的药物,因为它们在治疗因炎症介质释放而引起的疼痛、发热、发红和水肿方面有效。研究表明,NSAIDs的治疗作用和副作用均取决于环氧化酶(COX)抑制。COX同工型已被命名为组成型(COX-1)和诱导型(COX-2)。COX-1催化血小板、血管内皮、胃黏膜、肾脏、胰腺、胰岛、精囊和大脑中细胞保护性前列腺素的形成。各种生长因子、促炎剂、内毒素、有丝分裂原和肿瘤因子对COX-2的诱导表明,这种同工型可能在炎症等病理过程的诱导中起作用。众所周知,使用COX抑制剂进行治疗会带来许多副作用,包括胃肠道糜烂以及肾和肝功能不全。此类严重不良反应大多取决于COX-1抑制。由于致力于减少NSAIDs不良反应的研究,已开发出选择性COX-2抑制剂,如塞来昔布和罗非昔布。然而,许多数据表明这些药物的作用机制是多方向且复杂的。这些属于同一类别的药物或其衍生物具有不同的药理作用、副作用和效力,这意味着可能存在不止两种、五种甚至十种COX同工型。